Why INR is outside the therapeutic range in patients with acuteischemic stroke and atrial fibrillation

Introduction: Warfarin is still the primary drug used to prevent vascular events in patientswith atrial fibrillation (AF), especially in low-income countries. Therapeutic failure and non-adherenceare common causes of recurrent embolic events. The aim of this study was toinvestigate possible reasons why INR was outside the therapeutic range in patients presentingwith acute ischemic stroke and AF. Methods: This prospective study was performed over a ten-month period and all patientsadmitted with acute ischemic stroke were enrolled. Patients with AF who did not have INRwithin the therapeutic range (INR = 2-3) at the time of admission were identified. During a face-to-face interview, the reasons for INR being outside the therapeutic range were assessed basedon a prepared checklist. Results: During the study period, 810 patients had an acute ischemic stroke, of which 177 hadAF heart rhythm (22%). The median age was 76 (IQR: 71-83), and 87 (52%) were male. Of these177 patients, 44 (25%) had a previous history of AF ("previous AF" group) and 133 (75%) werediagnosed with AF during the current hospital admission ("new AF" group). Among patients onwarfarin but with INR outside the therapeutic range (29 in all), 20 (69%) did not see a physicianregularly and/or did not take medication according to the physician’s instructions. Conclusion: The most common reason for INR being outside the therapeutic range was patientslack of awareness of their heart disease (unrecognized AF). Other reasons included irregularvisits to the physician and drug non-adherence

The Effectiveness of Reality Therapy Training on Marital Engagement and Marital Engagement in Married Students in Azad University

The purpose of this study was to investigate the effectiveness of therapeutic reality on increasing the marital status of marital students. The research method was semi-experimental. In this research, the statistical society included all married students in the field of psychology of the master's degree. The sample consisted of 40 couples who were selected on purpose basis based on the criteria for entering and leaving. They were randomly divided into two groups of 20 couples and evaluated before and after the intervention using the research tools. The research tools included questionnaires of responsibility and marital disturbance scale. Data were analyzed using multivariate covariance analysis. The results of statistical analyzes showed that the reality of treatment with an effect size of 0.28 on increasing the level of accountability and having an effect of 0.33 on reduction of couple’s marital disturbance was effective. Conclusion: At the end of the course, students who received real-life education received learning that they had to choose responsible behaviors to achieve their goals, and to accept the consequences of their choices so that they would be disappointed with the family and Family members prevented

Evaluation of the GPM-IMERG Precipitation Product for Flood Modeling in a Semi-Arid Mountainous Basin in Morocco

International audienceA new precipitation dataset is provided since 2014 by the Global Precipitation Measurement (GPM) satellite constellation measurements combined in the Integrated Multi-satellite Retrievals for GPM (IMERG) algorithm. This recent GPM-IMERG dataset provides potentially useful precipitation data for regions with a low density of rain gauges. The main objective of this study is to evaluate the accuracy of the near real-time product (IMERG-E) compared to observed rainfall and its suitability for hydrological modeling over a mountainous watershed in Morocco, the Ghdat located upstream the city of Marrakech. Several statistical indices have been computed and a hydrological model has been driven with IMERG-E rainfall to estimate its suitability to simulate floods during the period from 2011 to 2018. The following results were obtained: (1) Compared to the rain gauge data, satellite precipitation data overestimates rainfall amounts with a relative bias of +35.61% (2) In terms of the precipitation detection capability, the IMERG-E performs better at reproducing the different precipitation statistics at the catchment scale, rather than at the pixel scale (3) The flood events can be simulated with the hydrological model using both the observed and the IMERG-E satellite precipitation data with a Nash–Sutcliffe efficiency coefficient of 0.58 and 0.71, respectively. The results of this study indicate that the GPM-IMERG-E precipitation estimates can be used for flood modeling in semi-arid regions such as Morocco and provide a valuable alternative to ground-based precipitation measurements

Economic Burden of Asthma in Northwest Iran

Background: The economic burden of asthma is a major public health concern. This study estimates the economic burden of asthma in Northwest of Iran.Methods: A longitudinal study was conducted between 2017 and 2018 in Tabriz, Iran using the Persian version of the Work Productivity and Activity Impairment (WPAI) questionnaire. Direct and indirect costs associated with asthma were estimated based on the societal perspective, prevalence-based approach, and bottom-up method. Annual indirect costs were estimated using the human capital (HC) method. The structural equation model was used to evaluate the relationship between costs, sex, and asthma severity. Results: A total of 621 patients with asthma were enrolled in the study. Significant differences were found between female and male patients for the mean cost of radiology (P=0.006), laboratory (P=0.028), and diagnostic (P=0.017) tests at baseline, and for laboratory (P=0.012), and diagnostic (P=0.027) tests at one-year follow-up. The more severe asthma, the more significant the costs for annual physician office visits (P=0.040) and medications (P=0.013). As asthma severity increased, significantly higher expenditures were observed in women for days lost from work at baseline (P=0.009) and one-year follow-up (P=0.001), and in men for productivity loss at work due to impairment at baseline (P=0.045). A significant association between indirect costs and the cost of impairment-related lost productivity at work (β=3.29, P<0.001), and between severe asthma and indirect costs (β=32.36, P<0.001) was observed. Conclusion: High costs are incurred by Iranian asthma patients, especially because of impairment-related productivity loss at work associated with asthma exacerbation

The Iranian blood pressure measurement campaign, 2019: study protocol and preliminary results

Purpose Hypertension is one of the most important risk factors for premature mortality and morbidity in Iran. The objective of the Iranian blood pressure (BP) measurement campaign was to identify individuals with raised blood pressure and providing appropriate care and increase the awareness among the public and policymakers of the importance of tackling hypertension. Methods The campaign was conducted in two phases. The first (communication) phase started on May 17th (International Hypertension Day). The second phase started on June 8th, 2019, and lasted up to July 7th during which, blood pressures were measured. The target population was Iranians aged >= 30 years. Participants voluntarily referred to health houses in rural and health posts and comprehensive health centers in urban areas in the setting of the Primary Health Care network. Additionally, over 13,700 temporary stations were set up in highly visited places in urban areas. Volunteer healthcare staff interviewed the participants, measured their BP, and provided them with lifestyle advice and knowledge of the risks and consequences of high blood pressure. They referred participants to physicians in case their BP was high. Participants immediately received a text message containing the relevant advice based on their measured BP and their past history. Results Blood pressure was measured for a total of 26,678,394 participants in the campaign. A total of 13,722,148 participants (51.4%) were female. The mean age was 46 +/- 14.1 years. Among total participants, 15,012,693 adults (56.3%) with no past history of hypertension had normal BP, 7,959,288 participants had BP in the prehypertension range (29.8%), and finally, 3,706,413 participants (13.9%) had either past medical history of hypertension, used medications, or had high BP measured in the campaign. Conclusion The campaign was feasible with the objective to increase the awareness among the public and policymakers of the importance of tackling hypertension in Iran

Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

Background: FGFR alterations are reported across various malignancies and might act as oncogenic drivers in multiple histologies. Erdafitinib is an oral, selective pan-FGFR tyrosine kinase inhibitor with activity in FGFR-altered advanced urothelial carcinoma. We aimed to evaluate the safety and activity of erdafitinib in previously treated patients with FGFR-altered advanced solid tumours. Methods: The single-arm, phase 2 RAGNAR study was conducted at 156 investigative centres (hospitals or oncology practices that are qualified oncology study centres) across 15 countries. The study consisted of four cohorts based on tumour histology and patient age; the results reported in this Article are for the primary cohort of the study, defined as the Broad Panel Cohort, which was histology-agnostic. We recruited patients aged 12 years or older with advanced or metastatic tumours of any histology (except urothelial cancer) with predefined FGFR1-4 alterations (mutations or fusions according to local or central testing). Eligible patients had disease progression on at least one previous line of systemic therapy and no alternative standard therapy available to them, and an Eastern Cooperative Oncology Group performance status of 0-1 (or equivalent for adolescents aged 12-17 years). Patients received once-daily oral erdafitinib (8 mg/day with provision for pharmacodynamically guided up-titration to 9 mg/day) on a continuous 21-day cycle until disease progression or intolerable toxicity. The primary endpoint was objective response rate by independent review committee according to Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1, or Response Assessment In Neuro-Oncology (RANO). The primary analysis was conducted on the treated population of the Broad Panel Cohort. This ongoing study is registered with ClinicalTrials.gov, number NCT04083976. Findings: Patients were recruited between Dec 5, 2019, and Feb 15, 2022. Of 217 patients treated with erdafitinib, 97 (45%) patients were female and 120 (55%) were male. The data cutoff was Aug 15, 2022. At a median follow-up of 17·9 months (IQR 13·6-23·9), an objective response was observed in 64 (30% [95% CI 24-36]) of 217 patients across 16 distinct tumour types. The most common grade 3 or higher treatment-emergent adverse events related to erdafitinib were stomatitis (25 [12%]), palmar-plantar erythrodysaesthesia syndrome (12 [6%]), and hyperphosphataemia (11 [5%]). The most commonly occurring serious treatment-related adverse events (grade 3 or higher) were stomatitis in four (2%) patients and diarrhoea in two (1%). There were no treatment-related deaths. Interpretation: RAGNAR results show clinical benefit for erdafitinib in the tumour-agnostic setting in patients with advanced solid tumours with susceptible FGFR alterations who have exhausted other treatment options. These results support the continued development of FGFR inhibitors in patients with advanced solid tumours